Tags

Type your tag names separated by a space and hit enter

COVID-19 Susceptibility in chronic obstructive pulmonary disease.
Eur J Clin Invest. 2020 Oct; 50(10):e13382.EJ

Abstract

In barely nine months, the pandemic known as COVID-19 has spread over 200 countries, affecting more than 22 million people and causing over than 786 000 deaths. Elderly people and patients with previous comorbidities such as hypertension and diabetes are at an increased risk to suffer a poor prognosis after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Although the same could be expected from patients with chronic obstructive pulmonary disease (COPD), current epidemiological data are conflicting. This could lead to a reduction of precautionary measures in these patients, in the context of a particularly complex global health crisis. Most COPD patients have a long history of smoking or exposure to other harmful particles or gases, capable of impairing pulmonary defences even years after the absence of exposure. Moreover, COPD is characterized by an ongoing immune dysfunction, which affects both pulmonary and systemic cellular and molecular inflammatory mediators. Consequently, increased susceptibility to viral respiratory infections have been reported in COPD, often worsened by bacterial co-infections and leading to serious clinical outcomes. The present paper is an up-to-date review that discusses the available research regarding the implications of coronavirus infection in COPD. Although validation in large studies is still needed, COPD likely increases SARS-CoV-2 susceptibility and increases COVID-19 severity. Hence, specific mechanisms to monitor and assess COPD patients should be addressed in the current pandemic.

Authors+Show Affiliations

Laboratory of Cellular and Molecular Pathology, Facultad de Ciencias de la Salud, Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Talca, Chile.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32780415

Citation

Olloquequi, Jordi. "COVID-19 Susceptibility in Chronic Obstructive Pulmonary Disease." European Journal of Clinical Investigation, vol. 50, no. 10, 2020, pp. e13382.
Olloquequi J. COVID-19 Susceptibility in chronic obstructive pulmonary disease. Eur J Clin Invest. 2020;50(10):e13382.
Olloquequi, J. (2020). COVID-19 Susceptibility in chronic obstructive pulmonary disease. European Journal of Clinical Investigation, 50(10), e13382. https://doi.org/10.1111/eci.13382
Olloquequi J. COVID-19 Susceptibility in Chronic Obstructive Pulmonary Disease. Eur J Clin Invest. 2020;50(10):e13382. PubMed PMID: 32780415.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COVID-19 Susceptibility in chronic obstructive pulmonary disease. A1 - Olloquequi,Jordi, Y1 - 2020/09/02/ PY - 2020/07/02/received PY - 2020/08/03/revised PY - 2020/08/06/accepted PY - 2020/8/12/pubmed PY - 2020/10/3/medline PY - 2020/8/12/entrez KW - COPD KW - SARS-CoV-2 KW - biomass smoke KW - coronavirus KW - pneumonia KW - smoking SP - e13382 EP - e13382 JF - European journal of clinical investigation JO - Eur J Clin Invest VL - 50 IS - 10 N2 - In barely nine months, the pandemic known as COVID-19 has spread over 200 countries, affecting more than 22 million people and causing over than 786 000 deaths. Elderly people and patients with previous comorbidities such as hypertension and diabetes are at an increased risk to suffer a poor prognosis after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Although the same could be expected from patients with chronic obstructive pulmonary disease (COPD), current epidemiological data are conflicting. This could lead to a reduction of precautionary measures in these patients, in the context of a particularly complex global health crisis. Most COPD patients have a long history of smoking or exposure to other harmful particles or gases, capable of impairing pulmonary defences even years after the absence of exposure. Moreover, COPD is characterized by an ongoing immune dysfunction, which affects both pulmonary and systemic cellular and molecular inflammatory mediators. Consequently, increased susceptibility to viral respiratory infections have been reported in COPD, often worsened by bacterial co-infections and leading to serious clinical outcomes. The present paper is an up-to-date review that discusses the available research regarding the implications of coronavirus infection in COPD. Although validation in large studies is still needed, COPD likely increases SARS-CoV-2 susceptibility and increases COVID-19 severity. Hence, specific mechanisms to monitor and assess COPD patients should be addressed in the current pandemic. SN - 1365-2362 UR - https://www.unboundmedicine.com/medline/citation/32780415/COVID_19_Susceptibility_in_chronic_obstructive_pulmonary_disease_ L2 - https://doi.org/10.1111/eci.13382 DB - PRIME DP - Unbound Medicine ER -